Cypher, Taxus Perform Equally Well In Trials, Registries – Meier Analysis
This article was originally published in The Gray Sheet
Executive Summary
The overall clinical performance of Boston Scientific's Taxus and J&J/Cordis' Cypher drug-eluting coronary stents is practically equivalent, according to Bernard Meier, MD, University Hospital, Bern, Switzerland
You may also be interested in...
REALITY delayed
Johnson & Johnson/Cordis will announce results of its REALITY trial, comparing Cypher sirolimus-eluting stents with Boston Scientific Taxus paclitaxel-eluting stents, at the American College of Cardiology meeting in March in Orlando, instead of at the November American Heart Association meeting in New Orleans, as previously planned, the firm announced Sept. 14 (1"The Gray Sheet" May 10, 2004, p. 6)...
REALITY delayed
Johnson & Johnson/Cordis will announce results of its REALITY trial, comparing Cypher sirolimus-eluting stents with Boston Scientific Taxus paclitaxel-eluting stents, at the American College of Cardiology meeting in March in Orlando, instead of at the November American Heart Association meeting in New Orleans, as previously planned, the firm announced Sept. 14 (1"The Gray Sheet" May 10, 2004, p. 6)...
FDA stays tuned to Taxus adverse events
Agency pledges to keep the public apprised of complaints related to the Boston Scientific paclitaxel-eluting stent, but says collected data detailing 28 Taxus incidents to date are insufficient to justify a formal solicitation similar to last October's "web notification" about J&J/Cordis' Cypher thrombosis rates. Some physicians have reported that the Taxus delivery system resists extraction after stent deployment, possibly due to improper balloon deflation. The incident rate is about 11.8 complaints per 1,000 used, Boston Scientific says, attributing the problems to physicians unfamiliar with the system (1"The Gray Sheet" April 26, 2004, p. 5)...